Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Investor's Business Daily on MSN
Moderna stock gets healthy relative strength rating jump
On Tuesday, Moderna MRNA got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 73. This exclusive rating ...
Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...
Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...
Moderna (MRNA) has jumped back into focus after its JPMorgan Healthcare Conference update, where management lifted the 2025 ...
We recently published 10 Stocks Jim Cramer Talked About. Moderna Inc. (NASDAQ:MRNA) is one of the stocks on Jim Cramer talked ...
I agree to the Terms of Use , Privacy Notice and Cookie Notice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback